Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD

Hepatology - Tập 72 Số 5 - Trang 1605-1616 - 2020
James M. Paik1, Pegah Golabi1, Youssef Younossi2, Alita Mishra3, Zobair M. Younossi1,3
1Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, United States
2Center for Outcomes Research in Liver Diseases, Washington DC, United States
3Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, VA

Tóm tắt

Background and Aims Chronic hepatitis B virus (HBV), hepatitis C virus (HCV), nonalcoholic fatty liver disease (NAFLD), and alcohol‐associated liver disease (ALD) are main causes of chronic liver disease. We assessed the global incidence, mortality, and disability‐adjusted life‐years (DALYs) related to chronic liver disease (primary liver cancer [LC] and cirrhosis). Approach and Results We obtained data from the 2017 Global Burden of Disease study. In 2017, there were 2.14 million liver‐related deaths (2.06‐2.30 million), representing an 11.4% increase since 2012 (16.0% increase in LC deaths; 8.7% increase in cirrhosis deaths). LC and cirrhosis accounted for 38.3% and 61.7%, respectively, of liver deaths (LC and cirrhosis deaths were related to HBV [39% and 29%], HCV [29% and 26%], ALD [16% and 25%], and NAFLD [8% and 9%]). Between 2012 and 2017, age‐standardized incidence rate, age‐standardized death rate (ASDR), and age‐standardized DALY rate increased for LC from 11.1 to 11.8, 10.1 to 10.2, and 250.4 to 253.6 per 100,000, respectively. Although age‐standardized incidence rate for cirrhosis increased from 66.0 to 66.3, ASDR and age‐standardized DALY rate decreased from 17.1 to 16.5 and 532.9 to 510.7, respectively. The largest increase in ASDR for LC occurred in Eastern Europe (annual percent change [APC] = 2.18% [0.89%‐3.49%]), whereas the largest decrease occurred in high‐income Asia Pacific (APC = −2.88% [−3.58 to −2.18%]). ASDR for LC‐NAFLD and ALD increased annually by 1.42% (1.00%‐1.83%) and 0.53% (0.08‐0.89), respectively, whereas there were no increases for HBV (P = 0.224) and HCV (P = 0.054). ASDR for cirrhosis‐NAFLD increased (APC = 0.29% [0.01%‐0.59%]) but decreased for ALD (APC = −0.44% [−0.78% to −0.40%]), HCV (APC = −0.50% [−0.81% to −0.18%]), and HBV (APC = −1.43% [−1.71% to −0.40%]). Conclusions From 2012 to 2017, the global burden of LC and cirrhosis has increased. Viral hepatitis remains the most common cause of liver deaths, and NAFLD is the most rapidly growing contributor to liver mortality and morbidity.

Từ khóa


Tài liệu tham khảo

2019, Burden of liver diseases in the world, J Hepatol, 70, 151, 10.1016/j.jhep.2018.09.014

2016, Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver‐related morbidity and mortality, Gastroenterology, 150, 1778, 10.1053/j.gastro.2016.03.005

2019, A comprehensive review of patient‐reported outcomes in patients with chronic liver diseases, J Clin Gastroenterol, 53, 331, 10.1097/MCG.0000000000001179

2019, Epidemiology and management of hepatocellular carcinoma, Gastroenterology, 156, 477, 10.1053/j.gastro.2018.08.065

2017, Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Cancer Control, 24, 1073274817729245

2019, Epidemiology of chronic liver diseases in the USA in the past three decades, Gut

2019, The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta‐analysis, J Hepatol, 71, 798

2011, The global obesity pandemic: shaped by global drivers and local environments, Lancet, 378, 804, 10.1016/S0140-6736(11)60813-1

2017, Health effects of overweight and obesity in 195 countries over 25 years, N Engl J Med, 377, 13, 10.1056/NEJMoa1614362

2018, Global, regional, and national age‐sex‐specific mortality for 282 causes of death in 195 countries and territories, 1980‐2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet, 392, 1736, 10.1016/S0140-6736(18)32203-7

2018, Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990‐2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet, 392, 1789, 10.1016/S0140-6736(18)32279-7

2010, Algorithms for enhancing public health utility of national causes‐of‐death data, Popul Health Metr, 8, 9, 10.1186/1478-7954-8-9

2012, Modeling causes of death: an integrated approach using CODEm, Popul Health Metr, 10, 1, 10.1186/1478-7954-10-1

2018, The state of US health, 1990‐2016: burden of diseases, injuries, and risk factors among US states, JAMA, 319, 1444, 10.1001/jama.2018.0158

2012, GBD 2010: design, definitions, and metrics, Lancet, 380, 2063, 10.1016/S0140-6736(12)61899-6

2018, The increase in mortality related to chronic liver disease is explained by non‐alcoholic fatty liver disease (NAFLD), Hepatology, 68, 453a

2019, Mortality related to nonalcoholic fatty liver disease is increasing in the United States, Hepatol Commun, 3, 1459, 10.1002/hep4.1419

2017, Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation, Gastroenterology, 152, 1090, 10.1053/j.gastro.2017.01.003

2018, Mortality due to cirrhosis and liver cancer in the United States, 1999‐2016: observational study, BMJ, 362, k2817

2015, Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001‐2013, Gastroenterology, 149, 1471, 10.1053/j.gastro.2015.07.056

2007, The cirrhosis epidemic in the UK: evaluating the causes in a European context, Expert Rev Gastroenterol Hepatol, 1, 41, 10.1586/17474124.1.1.41

2016, Decreasing mortality among Danish alcoholic cirrhosis patients: a nationwide cohort study, Am J Gastroenterol, 111, 817, 10.1038/ajg.2016.107

2017, Trends in 30‐day and 1‐year mortality among patients hospitalized with cirrhosis from 2004 to 2013, Am J Gastroenterol, 112, 1287, 10.1038/ajg.2017.175

2017, Global trends and predictions in hepatocellular carcinoma mortality, J Hepatol, 67, 302, 10.1016/j.jhep.2017.03.011

2018, Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease, Hepatology, 67, 123, 10.1002/hep.29466

2018, Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies, J Hepatol, 69, 718, 10.1016/j.jhep.2018.05.011

2014, Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry, J Clin Gastroenterol, 48, 279, 10.1097/MCG.0b013e3182a8a793

2019, Among Medicare patients with hepatocellular carcinoma, non‐alcoholic fatty liver disease is the most common etiology and cause of mortality, J Clin Gastroenterol

2019, Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates, Clin Gastroenterol Hepatol, 17, 748, 10.1016/j.cgh.2018.05.057

2019, Changing trends in etiology‐based and ethnicity‐based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States, Hepatology, 69, 1064, 10.1002/hep.30161

2019, The changing epidemiology of liver diseases in the Asia‐Pacific region, Nat Rev Gastroenterol Hepatol, 16, 57, 10.1038/s41575-018-0055-0

2017, Global trends in the burden of liver cancer, J Surg Oncol, 115, 591, 10.1002/jso.24518

2017, Deaths from liver cancer continue to rise in Australia: is elimination by 2030 possible?, Intern Med J, 47, 604, 10.1111/imj.13393

2017, The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015, JAMA Oncol, 3, 1683, 10.1001/jamaoncol.2017.3055

2017, Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012, Gastroenterology, 152, 812, 10.1053/j.gastro.2016.11.020

2015, Emerging trends in hepatocellular carcinoma incidence and mortality, Hepatology, 61, 191, 10.1002/hep.27388

2008, Trends in mortality from hepatocellular carcinoma in Europe, 1980‐2004, Hepatology, 48, 137, 10.1002/hep.22312

2018, Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan, J Viral Hepatol, 25, 945, 10.1111/jvh.12886

2017, Risk of hepatocellular cancer in HCV patients treated with direct‐acting antiviral agents, Gastroenterology, 153, 996, 10.1053/j.gastro.2017.06.012

2016, Outcomes after successful direct‐acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis, J Hepatol, 65, 741, 10.1016/j.jhep.2016.06.019

2010, Disease progression of non‐alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years, Gut, 59, 969, 10.1136/gut.2009.205088

2016, Global epidemiology of nonalcoholic fatty liver disease: meta‐analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431

Thông tin
Thông tin xuất bản

Hepatology

Tập 72 Số 5

1605-1616

Thông tin tác giả